Navigating Treatment Strategies in the
Management of Metastatic Bladder Cancer: Expert Perspectives in
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2019 Fall Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from January 1, 2020 to January 1, 2021
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by an
educational grant from
Merck Sharp & Dohme Corp.
Bladder cancer, also known as urothelial carcinoma, is the ninth
leading cause of cancer death in the United States. Before the
advent of new treatments in recent years, the basic management of
this illness has remained unchanged for decades. Long-term survival
for people diagnosed with advanced bladder cancer is poor, with
approximately 5% of patients surviving for 5 years or more. New and
emerging treatments, in particular, immune checkpoint inhibitors
have changed the treatment paradigm. Checkpoint inhibitors have
shown activity in patients with metastatic bladder cancer in both
the first and second-line settings. Some of the new
immunotherapeutic options target a protein known as PD-L1 that is
expressed at high levels on some cancer cells, while others target
PD-1, the receptor protein for PD-L1, on immune cells. Normally,
binding of PD-L1 to PD-1 tamps down immune activity. By preventing
the interaction between PD-L1 and PD-1, all of these new options can
allow the immune system to be more active against tumor cells.
Upon completion of this
activity, participants will be able to:
Analyze the role of immune
checkpoint inhibitors in the first-line treatment of metastatic
Explore efficacy and safety profiles
of current and emerging immune checkpoint inhibitors for the
treatment of metastatic bladder cancer
Assess the latest clinical evidence
regarding predictors of response to immunotherapy in metastatic
Identify patients who would
potentially benefit from immunotherapies in metastatic bladder
Define strategies for anticipating,
recognizing, and managing immune-related adverse events of
immunotherapy in patients with metastatic bladder cancer
||Matthew Galsky, MD
Professor of Medicine
Genitourinary Medical Oncology
Icahn School of Medicine at Mount Sinai
Director, Novel Therapeutics Unit
Tisch Cancer Institute
serves on an advisory board for AstraZeneca, BMS,
Genentech, Merck, and Pfizer. He has received
grant/research support from AstraZeneca, BMS, Genentech,
and Merck. His presentation has been peer reviewed for
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Will Williams has no relevant financial relationships to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 creditsTM.
The American Association of Managed Care Nurses (AAMCN) is
accredited as a provider of nursing continuing professional
development by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hour toward CMCN recertification
This presentation is supported by
an educational grant from
Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue